Celsion Announces FDA Clearance of the OPTIMA Study - A Pivotal Phase III Trial of ThermoDox in Primary Liver Cancer

Study Developed in Consultation with Clinical Advisors, Statistical Experts and FDA Compelling Survival Data Supports Development Trial Advances Global Regulatory Strategy in Key Markets LAWRENCEVILLE, N.J., Feb. 24, 2014 -- (Healthcare Sales & Ma... Biopharmaceuticals, Drug Delivery, Oncology, FDACelsion, ThermoDox, liposome, hepatocellular carcinoma, liver cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news